Open the map

BiogenBIIB

Biotech & innovation · NASDAQ · USA

$218.43
Down 1.7% todayClose

Up 26.2% this year and +1.1% since June 26, behind the life science sector at +10.7%. Biogen supplies 1 mapped company and buys from 1.

Market cap
$32.1B
This year
+26.2%
1 year
+45.9%
P/E
38.4
P/S
3.2
P/B
1.7

Price vs the life science sector

since Jun 26BIIBLife science sector, equal weight
Biogen (BIIB) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. BIIB: +1.1% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−10%0%+10%Jun 26AugSepOct 8BIIB +1.1%Sector +10.7% Biogen (BIIB) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. BIIB: +1.1% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−10%0%+10%Jun 26AugSepOct 8BIIB+1.1%Sector+10.7%

Supply chain

1 supplier · 1 customer
SUPPLIERS →→ CUSTOMERSIQVIA Holdings (IQV)IQVIQVIA Holdings+0.3%McKesson (MCK)MCKMcKesson+2.2%BIIBBiogen

Suppliers 1

Customers 1

Open the full chain →

About Biogen

Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.

Theme exposure

BiotechNeurologyAlzheimer's

Products

  • Alzheimer's (Leqembi)
  • Multiple sclerosis
  • Rare diseases

Competitors

Risks

  • Leqembi uptake
  • Declining MS revenue

Same segment: Biotech & innovation

Innovation-driven biotech companies focused on novel treatment modalities. Segment 3 of 8 in the Medicine, pharma & life science value chain.

AmgenAMGN−1.4%Gilead SciencesGILD+0.2%Vertex PharmaceuticalsVRTX−0.5%ModernaMRNA+0.3%RegeneronREGN−0.3%Alnylam PharmaceuticalsALNY+0.1%United TherapeuticsUTHR−2.2%IncyteINCY−0.6%

Compare BIIB

Side by side with the largest companies in the same segment.

BIIB vs AMGNBIIB vs GILDBIIB vs VRTXBIIB vs MRNABIIB vs REGNBIIB vs ALNY

See where Biogen sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →